n6 has announced substantial expansions to its distribution partnerships, enhancing access to its iconPCR™ instruments and AutoNorm technology across Europe, the Middle East, and Africa. These developments increase the company’s global footprint, with products now available in over 25 countries.
The company has recently broadened its presence in Western Europe, particularly in Germany and neighboring areas. Morpho Biotech, already distributing n6 products in Belgium, Luxembourg, and the Netherlands, has extended its partnership to include Germany. The company is also collaborating with n6 to improve customer support in France.
“What excites us most about iconPCR is the impact AutoNorm can have across the NGS workflow,” said Koos Kranenborg, General Manager of Morpho Biotech. “Rather than treating every sample identically and correcting for variability afterward, AutoNorm intelligently controls amplification at the individual-sample level. We have already seen a positive impact at several customer sites and believe AutoNorm has the potential to become an important new standard in NGS library preparation.”
In addition to its European expansion, n6 has added Bioseen Trading LLC in the Gulf Region and Inqaba Biotec in Africa to its distribution network. These partnerships aim to make iconPCR more accessible while providing local technical support. n6’s distribution network already spans the Americas, Europe, and the Asia-Pacific region, collaborating with partners such as Witec and Bonsai Lab.
“Our mission at n6 is to make high-quality, scalable NGS library prep accessible to more scientists, no matter where they are based,” said Alex Hutcheson, VP of Sales and Support at n6. “Expanding our footprint across Western Europe, the Middle East, and Africa is a critical step toward that goal. We’re excited to deepen our collaborations with distributors who understand their local markets and can help us bring iconPCR and AutoNorm to labs that are ready to move beyond legacy amplification and normalization workflows.”
As n6’s channel network continues to grow, the company plans to invest in educational initiatives and technical support with its distributors. In the latter half of 2026, n6 and its partners will participate in several scientific meetings, including EMBL’s “Transcription and Chromatin” conference in Heidelberg. An n6 customer, Ferris Jung, will lead a workshop at this event, further solidifying the company’s engagement in the scientific community.
The iconPCR platform with AutoNorm is distinctive for its real-time control of amplification and automated normalization, facilitating the streamlined creation of sequencing-ready libraries. This technology enhances workflows across a variety of applications, including microbiome studies, oncology, and genomics.
Hutcheson remarked on the growing adoption of n6 products, stating, “With more than 25 countries now running iconPCR and AutoNorm-enabled workflows, we’re seeing the same pattern repeat. Teams start by solving one painful bottleneck in their library prep process, and quickly realize they can standardize on iconPCR across multiple applications.”
